Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2014 | |
| Assets | |
| Current Assets | |
| Cash & Cash Equivalents | 2,650 |
| Other current assets | 80 |
| TOTAL | $2,730 |
| Non-Current Assets | |
| Other Non-Current Assets | 30 |
| TOTAL | $30 |
| Total Assets | $2,930 |
| Liabilities | |
| Current Liabilities | |
| Accounts payable and accrued liabilities | 340 |
| Accrued Expenses | 710 |
| TOTAL | $1,050 |
| Non-Current Liabilities | |
| TOTAL | $N/A |
| Total Liabilities | $1,050 |
| Shareholders' Equity | |
| Common Shares | 810 |
| Retained earnings | -12,280 |
| Other shareholders' equity | 13,340 |
| TOTAL | $1,870 |
| Total Liabilities And Equity | $2,920 |